Intravesical Mycobacterium brumae triggers both local and systemic immunotherapeutic responses against bladder cancer in mice

[1]  Sam S. Chang.  Re: Curcumin as Treatment for Bladder Cancer: A Preclinical Study of Cyclodextrin-Curcumin Complex and BCG as Intravesical Treatment in an Orthotopic Bladder Cancer Rat Model. , 2019, The Journal of urology.

[2]  A. Chakrabarty,et al.  Microbial Infections and Cancer Therapy , 2019 .

[3]  D. Molenaar,et al.  Naturally Fermented Milk From Northern Senegal: Bacterial Community Composition and Probiotic Enrichment With Lactobacillus rhamnosus , 2018, Front. Microbiol..

[4]  Yusuke Nakamura,et al.  Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette–Guerin for patients with non-muscle invasive bladder cancer , 2018, Cancer immunology, immunotherapy : CII.

[5]  J. Witjes,et al.  Curcumin as Treatment for Bladder Cancer: A Preclinical Study of Cyclodextrin-Curcumin Complex and BCG as Intravesical Treatment in an Orthotopic Bladder Cancer Rat Model , 2018, BioMed research international.

[6]  T. D. de Reijke,et al.  Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer , 2018, Expert opinion on emerging drugs.

[7]  A. Melcher,et al.  Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus , 2018, Molecular therapy oncolytics.

[8]  R. Hoffman,et al.  Bacterial Therapy of Cancer: Promises, Limitations, and Insights for Future Directions , 2018, Front. Microbiol..

[9]  E. Julián,et al.  Mycobacteria-Derived Agents for the Treatment of Urological and Renal Cancers , 2017, Mycobacterium - Research and Development.

[10]  L. Reis,et al.  Intravesical Immunomodulatory Imiquimod Enhances Bacillus Calmette‐Guérin Downregulation of Nonmuscle‐invasive Bladder Cancer , 2017, Clinical genitourinary cancer.

[11]  S. Zubair,et al.  Evaluation of Aggregated Ag85B Antigen for Its Biophysical Properties, Immunogenicity, and Vaccination Potential in a Murine Model of Tuberculosis Infection , 2017, Front. Immunol..

[12]  A. Morales.  BCG: A throwback from the stone age of vaccines opened the path for bladder cancer immunotherapy. , 2017, The Canadian journal of urology.

[13]  D. Zaharoff,et al.  Immunological mechanisms of intravesical chitosan/interleukin-12 immunotherapy against murine bladder cancer , 2016, Oncoimmunology.

[14]  M. Cecchini,et al.  Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease , 2016, Scientific Reports.

[15]  Parminder Singh,et al.  Emerging role of checkpoint inhibition in localized bladder cancer. , 2016, Urologic oncology.

[16]  M. Cecchini,et al.  Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease , 2016, Scientific Reports.

[17]  Chunxiao Wu,et al.  Local Immune Stimulation by Intravesical Instillation of Baculovirus to Enable Bladder Cancer Therapy , 2016, Scientific Reports.

[18]  E. Julián,et al.  Mycobacteria emulsified in olive oil-in-water trigger a robust immune response in bladder cancer treatment , 2016, Scientific Reports.

[19]  G. Schäfer,et al.  Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer , 2016, Oncotarget.

[20]  E. Julián,et al.  Nonpathogenic Mycobacterium brumae Inhibits Bladder Cancer Growth In Vitro, Ex Vivo, and In Vivo. , 2016, European urology focus.

[21]  Shigui Yang,et al.  Corrigendum: The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes , 2016, Scientific Reports.

[22]  E. Julián,et al.  γ Irradiated Mycobacteria Enhance Survival in Bladder Tumor Bearing Mice Although Less Efficaciously than Live Mycobacteria. , 2016, The Journal of urology.

[23]  N. Vasdev,et al.  Immunotherapy for bladder cancer , 2015, Research and Reports in Urology.

[24]  E. Julián,et al.  Killed but metabolically active Mycobacterium bovis bacillus Calmette-Guérin retains the antitumor ability of live bacillus Calmette-Guérin. , 2014, The Journal of urology.

[25]  M. Glickman,et al.  The mechanism of action of BCG therapy for bladder cancer—a current perspective , 2014, Nature Reviews Urology.

[26]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. , 2013, European urology.

[27]  D. Lamm,et al.  Bacillus Calmette‐Guérin immunotherapy for genitourinary cancer , 2013, BJU international.

[28]  E. Julián,et al.  Connaught and Russian strains showed the highest direct antitumor effects of different Bacillus Calmette-Guérin substrains. , 2013, The Journal of urology.

[29]  E. Karpman.  Erratum to “Streamlined Approach for Infrapubic Placement of an Inflatable Penile Prosthesis” , 2012, Advances in Urology.

[30]  M. Newton,et al.  Bladder Cancer Immunotherapy: BCG and Beyond , 2012, Advances in urology.

[31]  M. Albert,et al.  Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer , 2012, Science Translational Medicine.

[32]  R. Mahendran,et al.  Tumor and Microenvironment Modification during Progression of Murine Orthotopic Bladder Cancer , 2011, Clinical & developmental immunology.

[33]  M. A. Ansari,et al.  RD Antigen Based Nanovaccine Imparts Long Term Protection by Inducing Memory Response against Experimental Murine Tuberculosis , 2011, PloS one.

[34]  L. Bonomo,et al.  Usefulness of Ultrasound Imaging in Detecting Psoriatic Arthritis of Fingers and Toes in Patients with Psoriasis , 2011, Clinical & developmental immunology.

[35]  P. Adam,et al.  Reactive antibodies against bacillus Calmette‐Guerin heat‐shock protein‐65 potentially predict the outcome of immunotherapy for high‐grade transitional cell carcinoma of the bladder , 2010, Cancer.

[36]  E. Julián,et al.  Increased levels of immunological markers in the respiratory tract but not in serum correlate with active pulmonary mycobacterial infection in mice. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[37]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. , 2008, European urology.

[38]  Y. Uekado,et al.  Intravesical instillation therapy with bacillus Calmette‐Guérin for superficial bladder cancer: Study of the mechanism of bacillus Calmette‐Guérin immunotherapy , 2007, International journal of urology : official journal of the Japanese Urological Association.

[39]  K. Kurth,et al.  Role of urothelial cells in BCG immunotherapy for superficial bladder cancer , 2004, British Journal of Cancer.

[40]  T. Reijke,et al.  Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer , 2004, Urological Research.

[41]  P. Steerenberg,et al.  Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin , 2004, Cancer Immunology, Immunotherapy.

[42]  A. Böhle,et al.  IFN‐gamma and IL‐12 but not IL‐10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer , 2002, Clinical and experimental immunology.

[43]  T. Ratliff,et al.  NK cells are essential for effective BCG immunotherapy , 2001, International journal of cancer.

[44]  E. Julián,et al.  An ELISA for five glycolipids from the cell wall of Mycobacterium tuberculosis: Tween 20 interference in the assay. , 2001, Journal of immunological methods.

[45]  T. Ratliff,et al.  Role of a bacillus calmette‐guérin fibronectin attachment protein in BCG‐induced antitumor activity , 2000, International journal of cancer.

[46]  Y. Luo,et al.  Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin. , 1999, Journal of immunology.

[47]  F. Mascart,et al.  Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette–Guérin (BCG) in patients with superficial bladder cancer , 1997, Clinical and experimental immunology.

[48]  S. Prescott,et al.  Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. , 1995, The Journal of urology.

[49]  A. Böhle,et al.  Towards an Understanding of the Mode of Action of Bacillus Calmette-Guérin-Therapy in Bladder Cancer Treatment, Especially with Regard to the Role of Fibronectin , 1992, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[50]  R. Coffman,et al.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. , 1986, Journal of immunology.

[51]  D. Lamm,et al.  BCG immunotherapy of bladder cancer: Inhibition of tumor recurrence and associated immune responses , 1981, Cancer.

[52]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.

[53]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.